valvular heart disease
Conditions
Interventions
Control group:SAPB combine TTMPB (the same amount of saline)
Treatment group:SAPB combine TTMPB (0.5% ropivacaine 30 mL)
Sponsors
The First Affiliated Hospital of Jinan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients voluntarily participate in this study and sign subject informed consent; 2. ASA graded <= IV, NYHA graded <= Class III; 3. Age 18~65 years old, male or female, body mass index 18~28 kg/m^2; 4. The first time to take totally thoracoscopic cardiac surgery.
Exclusion criteria
Exclusion criteria: 1. Having a history of right-sided thoracic surgery or chest deformity; 2. Allergy to ropivacaine and other anesthetics; 3. Patients with atrioventricuiar block and severe bradycardia; 4. Patients with acute heart failure; 5. Patients were unable to communicate normally due to mental status, intellectual disability, or other causes; 6. Infection, rupture, and coagulation at the puncture site or coagulation disorders; 7. Patients with a history of chronic pain or long-term use of analgesic medications; 8. Severe liver and kidney dysfunction; 9. Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Opioid dosage during operation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Indicators of enhanced recovery after surgery;Hemodynamic index;Postoperative VAS score;QoR-15 score; | — |
Countries
China
Contacts
Public ContactWang Hao
The First Affiliated Hospital of Jinan University
Outcome results
None listed